Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials

Journal of Alzheimer's Disease

Volumn 32, Issue 2, 2012, Pages 273-276

  Olsson, Bob ^a   Malmeström, Clas ^b   Basun, Hans ^c   Annas, Peter ^d   Höglund, Kina ^d   Lannfelt, Lars ^c   Andreasen, Niels ^e   Zetterberg, Henrik ^a   Blennow, Kaj ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; biomarker; cerebrospinal fluid; chitotriosidase; multiple sclerosis; stability

Indexed keywords

CHITOTRIOSIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NATALIZUMAB;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; CEREBROSPINAL FLUID; ENZYME ACTIVITY; ENZYME STABILITY; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 84867501199     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120931     Document Type: Article

References (13)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372, 1502-1517.
3. McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 47, 425-432.
4. Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
5. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, Mannens MM, Aerts JM (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273, 25680-25685.
6. Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93, 1288-1292.
7. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N(2007) Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 419, 18-22.
8. Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Mansson JE, Johansson JO, Olsson B, Wallin A, Svensson J, Blennow K, Zetterberg H (2011) Cerebrospinal fluid microglial markers in Alzheimer's disease: Elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 13, 151-159.
9. Watabe-Rudolph M, Song Z, Lausser L, Schnack C, Begus- Nahrmann Y, Scheithauer MO, Rettinger G, Otto M, Tumani H, Thal DR, Attems J, Jellinger KA, Kestler HA, von Arnim CA, Rudolph KL (2012) Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology 78, 569-577.
10. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356, 63-66.
11. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. (1993) Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177, 57-68.
12. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348, 15- 23.
13. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006)Arandomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354, 899- 910.